Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro

Journal of Cellular Physiology

Volumn 228, Issue 5, 2013, Pages 1127-1136

  Zolochevska, Olga ^a   Diaz Quiñones, Adriana O ^a   Ellis, Jayne ^a   Figueiredo, Marxa L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 27; PROTEINASE;

ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BONE CELL; BONE DEVELOPMENT; BONE METASTASIS; CANCER CELL; CELL DIFFERENTIATION; CELL INTERACTION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

BONE NEOPLASMS; CELL COMMUNICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84873845022     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24265     Document Type: Article

References (58)

1. Belouski SS, Wilkinson J, Thomas J, Kelley K, Wang SW, Suggs S, Ferbas J. 2010. Utility of lyophilized PMA and ionomycin to stimulate lymphocytes in whole blood for immunological assays. Cytometry B Clin Cytom 78:59-64.
2. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. 2003. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28-37.
3. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A. 2000. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164:1248-1253.
4. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. 2001. Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates. J Urol 166:2023-2031.
5. Bluyssen HA, Levy DE. 1997. Stat2 is a transcriptional activator that requires sequence-specific contacts provided by stat1 and p48 for stable interaction with DNA. J Biol Chem 272:4600-4605.
6. Boyce BF, Yoneda T, Guise TA. 1999. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6:333-347.
7. Brodeur MR, Brissette L, Falstrault L, Luangrath V, Moreau R. 2008. Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3. J Bone Miner Res 23:326-337.
8. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. 2000. Metastatic patterns of prostate cancer: An autopsy study of 1, 589 patients. Hum Pathol 31:578-583.
9. Carlin BI, Andriole GL. 2000. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88:2989-2994.
10. Clark PE, Torti FM. 2003. Prostate cancer and bone metastases: Medical treatment. Clin Orthop Relat Res 415 Suppl:S148-S157.
11. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I. 2010. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 16:4188-4197.
12. Coleman RE. 2001. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176.
13. Crabtree GR, Clipstone NA. 1994. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 63:1045-1083.
14. Engel MA, Neurath MF. 2010. Anticancer properties of the IL-12 family-Focus on colorectal cancer. Curr Med Chem 17:3303-3308.
15. Faccio R. 2011. Immune regulation of the tumor/bone vicious cycle. Ann NY Acad Sci 1237:71-78.
16. Feng XM, Chen XL, Liu N, Chen Z, Zhou YL, Han ZB, Zhang L, Han ZC. 2007. Interleukin-27 upregulates major histocompatibility complex class II expression in primary human endothelial cells through induction of major histocompatibility complex class II transactivator. Hum Immunol 68:965-972.
17. Feng JQ, Ye L, Schiavi S. 2009. Do osteocytes contribute to phosphate homeostasis? Curr Opin Nephrol Hypertens 18:285-291.
18. Fernandes H, Mentink A, Bank R, Stoop R, van Blitterswijk C, de Boer J. 2010. Endogenous collagen influences differentiation of human multipotent mesenchymal stromal cells. Tissue Eng A 16:1693-1702.
19. Furukawa M, Takaishi H, Takito J, Yoda M, Sakai S, Hikata T, Hakozaki A, Uchikawa S, Matsumoto M, Chiba K, Kimura T, Okada Y, Matsuo K, Yoshida H, Toyama Y. 2009. IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol 183:2397-2406.
20. Giannoudis PV, Kanakaris NK, Einhorn TA. 2007. Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: Review of the existing evidence. Osteoporos Int 18:1565-1581.
21. Goltzman D. 1997. Mechanisms of the development of osteoblastic metastases. Cancer 80:1581-1587.
22. Harre U, Keppeler H, Ipseiz N, Derer A, Poller K, Aigner M, Schett G, Herrmann M, Lauber K. 2012. Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity 45:612-619.
23. Helfrich MH, Nesbitt SA, Horton MA. 1992. Integrins on rat osteoclasts: Characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. J Bone Miner Res 7:345-351.
24. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T. 2004. Potent antitumor activity of interleukin-27. Cancer Res 64:1152-1156.
25. Jahnen-Dechent W, Heiss A, Schafer C, Ketteler M. 2011. Fetuin-A regulation of calcified matrix metabolism. Circ Res 108:1494-1509.
26. Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB. 2010. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum 62:402-413.
27. Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T, Wada S. 2007. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: Inhibitory effects on osteoclast differentiation. J Bone Miner Metab 25:277-285.
28. Kogawa M, Anderson PH, Findlay DM, Morris HA, Atkins GJ. 2010. The metabolism of 25-(OH) vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. J Steroid Biochem Mol Biol 121:277-280.
29. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488.
30. Li Y, Messina C, Bendaoud M, Fine DH, Schreiner H, Tsiagbe VK. 2010. Adaptive immune response in osteoclastic bone resorption induced by orally administered Aggregatibacter actinomycetemcomitans in a rat model of periodontal disease. Mol Oral Microbiol 25:275-292.
31. Lucas S, Ghilardi N, Li J, de Sauvage FJ. 2003. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci USA 100:15047-15052.
32. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S, Chinnaiyan AM. 2012. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res 71:5387-5392.
33. Marsell R, Einhorn TA. 2009. The role of endogenous bone morphogenetic proteins in normal skeletal repair. Injury 40:S4-S7.
34. Mikami Y, Asano M, Honda MJ, Takagi M. 2010. Bone morphogenetic protein 2 and dexamethasone synergistically increase alkaline phosphatase levels through JAK/STAT signaling in C3H10T1/2 cells. J Cell Physiol 223:123-133.
35. Mundy GR. 2002. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593.
36. Mundy GR, Guise TA. 1997. Hypercalcemia of malignancy. Am J Med 103:134-145.
37. Okamoto M, Murai J, Imai Y, Ikegami D, Kamiya N, Kato S, Mishina Y, Yoshikawa H, Tsumaki N. 2011. Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice. J Bone Miner Res 26:2511-2522.
38. Otomo H, Sakai A, Uchida S, Tanaka S, Watanuki M, Moriwaki S, Niida S, Nakamura T. 2007. Flt-1 tyrosine kinase-deficient homozygous mice result in decreased trabecular bone volume with reduced osteogenic potential. Bone 40:1494-1501.
39. Radcliff K, Tang TB, Lim J, Zhang Z, Abedin M, Demer LL, Tintut Y. 2005. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 96:398-400.
40. Roodman GD. 2004. Mechanisms of bone metastasis. N Engl J Med 350:1655-1664.
41. Rowe PS. 2012. Regulation of bone-renal mineral and energy metabolism: The PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 22:61-86.
42. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM. 2004. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: Role for CD8+ T cells. J Immunol 173:7170-7182.
43. Sameni M, Dosescu J, Yamada KM, Sloane BF, Cavallo-Medved D. 2008. Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells. Mol Imaging 7:199-213.
44. Singh S, Mak IW, Cowan RW, Turcotte R, Singh G, Ghert M. 2011. The role of TWIST as a regulator in giant cell tumor of bone. J Cell Biochem 112:2287-2295.
45. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600-605.
46. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H. 2003. Cutting edge: Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 170:4886-4890.
47. Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, Gilbert L, Nanes MS, Zayzafoon M, Guldberg R, Lamar DL, Singer MA, Lane TF, Kronenberg HM, Weitzmann MN, Pacifici R. 2009. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 10:229-240.
48. Venturi G, Monti E, Dalle Carbonare L, Corradi M, Gandini A, Valenti MT, Boner A, Antoniazzi F. 2012. A novel splicing mutation in FKBP10 causing osteogenesis imperfecta with a possible mineralization defect. Bone 50:343-349.
49. Wong MH, Stockler MR, Pavlakis N. 2012. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474.
50. Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger F, Peterlik M, Pietschmann P. 2006. Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A 77:75-83.
51. Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H, Hirose J, Omata Y, Yasuda H, Imamura T, Nakamura K, Tanaka S. 2011. Regulation of RANKL-induced osteoclastogenesis by TGF-beta through molecular interaction between Smad3 and Traf6. J Bone Miner Res 26:1447-1456.
52. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J. 2008. Antiproliferative activity of IL-27 on melanoma. J Immunol 180:6527-6535.
53. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. 2008. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 283:11535-11540.
54. Zhao M, Harris SE, Horn D, Geng Z, Nishimura R, Mundy GR, Chen D. 2002. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol 157:1049-1060.
55. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. 2007. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: Implications for osteolytic bone metastases. J Biol Chem 282:26656-26664.
56. Zhu S, Lee DA, Li S. 2010. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184:2348-2354.
57. Zolochevska O, Xia X, Williams BJ, Ramsay A, Li S, Figueiredo ML. 2011. Sonoporation delivery of Interleukin 27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Human Gene Ther 22:1537-1550.
58. Zolochevska O, Yu G, Gimble JM, Figueiredo ML. 2012. Pigment epithelial-derived factor and melanoma differentiation associated gene-7 cytokine gene therapies delivered by adipose-derived stromal/mesenchymal stem cells are effective in reducing prostate cancer cell growth. Stem Cells Dev 21:1112-1123.